Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6688MR)

This product GTTS-WQ6688MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6688MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ16016MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ15534MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ8437MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ12315MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ14074MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ8436MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ15081MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ2293MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW